Cefaclor AF: correlation of microbiology and clinical outcome

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Cefaclor exhibits activity against common respiratory pathogens like Haemophilus influenzae and Moraxella catarrhalis.
• First-generation cephalosporins typically target a range of susceptible bacterial pathogens.
• Advanced formulations aim to improve drug delivery and patient compliance.

Purpose of the Study:

• To evaluate the efficacy of cefaclor advanced formulation (cefaclor AF) in treating bacterial infections.
• To assess the antimicrobial spectrum of cefaclor, including activity against specific respiratory pathogens.
• To correlate in vitro antimicrobial susceptibility data with clinical outcomes in patients treated with cefaclor AF.

Main Methods:

• Clinical trials were conducted across multiple centers to assess cefaclor AF in respiratory, urinary, and skin infections.
• In vitro susceptibility testing was performed on selected bacterial pathogens isolated from clinical trial participants.
• Testing followed National Committee for Clinical Laboratory Standards (NCCLS) guidelines.

Main Results:

• Cefaclor AF demonstrated activity against Haemophilus influenzae and Moraxella catarrhalis.
• Clinical trials investigated cefaclor AF for various bacterial infections.
• In vitro susceptibility results generally showed excellent agreement with in vivo clinical responses.

Conclusions:

• Cefaclor AF is a viable therapeutic option for bacterial infections caused by susceptible pathogens.
• The advanced formulation of cefaclor allows for convenient once or twice daily dosing.
• The correlation between in vitro susceptibility and in vivo efficacy supports the use of cefaclor AF.